Overview

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Status:
Recruiting
Trial end date:
2023-10-21
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
Phase:
Phase 2
Details
Lead Sponsor:
Jason Robert Gotlib
Stanford University
Collaborator:
Incyte Corporation
Treatments:
Janus Kinase Inhibitors